ALK NSCLC MENA: Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
Study Details
Study Description
Brief Summary
Thet study aims to estimate the prevalence of ALK rearrangement in the Middle East North Africa population by using the Ventana ALK-IHC method for ALK protein detection in retrospective NSCLC clinical samples, & to evaluate the association of ALK rearrangement with clinical and pathological parameters of NSCLC patients in MENA.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
This is a retrospective, cross-sectional non-interventional epidemiology study to investigate the prevalence of ALK rearrangement in NSCLC patients in Middle East & North Africa. Approximately 700 retained tumor tissue specimens (tissue block) of patients previously diagnosed with NSCLC will be selected & subjected to ALK immune-staining using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody combined with OptiView Benchmark System in 6-8 centers in 5-7 countries in the MENA region.
The tissue samples of NSCLC cases will be retrieved from tissue banks of the molecular diagnostic units & pathology departments in these study centers. The histological diagnosis will be confirmed by the pathologists. The retained samples will then be tested by performing the Ventana ALK-IHC to assess the absence or presence of the ALK rearrangement by the detection of the ALK protein in formalin-fixed, paraffin-embedded NSCLC stored tissue samples using Ventana anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody (Roche Diagnostics GmbH) in the selected study centers. The results of ALK testing within this study population will then be used to establish the prevalence of ALK rearrangement in MENA NSCLC patients.
The patients' characteristics, demographic, clinical and pathologic parameters will be obtained from their medical records & analyzed to determine any association with the presence of the EML4-ALK fusion gene in MENA NSCLC patients.
The assessment of concordance of the results between FISH & IHC will be done in 2-3 centers. Results of FISH testing will be collected & recorded, if the retained tissue samples had been previously tested. If not, the Vysis FISH test will be performed, to assess the concordance between the results obtained using Vysis Break-apart FISH & Ventana IHC testing methods for ALK rearrangement detection.
Study Design
Outcome Measures
Primary Outcome Measures
- Percentage of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement [3 years]
Participants with prevalence of ALK rearrangement were positive for ALK: defined as presence of strong granular cytoplasmic staining in tumor cells (any percentage of positive tumor cells).
Secondary Outcome Measures
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Gender [3 years]
In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the gender of study participants.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Race [3 years]
In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the race of study participants.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Smoking History [3 years]
In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the smoking history of study participants as participants who never smoked, current smoker and ex-smoker.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Tumor Histologic Diagnosis [3 years]
In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the diagnosis of tumor histology of study participants.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Tumor Stage [3 years]
In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the tumor stage of study participants.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Treatment Type [3 years]
In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the treatment type of study participants.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Progression Free Survival (PFS) [3 years]
In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the PFS of study participants.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Line of Therapy [3 years]
In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the line of therapy of study participants.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Overall Response (OR) [3 years]
Percentage of participants with best overall response. Complete response (CR) is equal to (=) disappearance of all target lesions. Partial Response (PR) = greater than equal to (>=) 30% decrease in sum of longest dimensions of lesions taking as reference baseline sum longest dimensions. Progressive disease (PD) >= 20% increase in sum of longest dimensions of lesions taking as a reference smallest sum of the longest dimensions since treatment start, or the appearance of >= 1 new lesion. Stable disease (SD) =neither shrinkage for PR or increase for PD taking as reference smallest sum of longest dimensions since treatment start.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Participant's Status [3 years]
In this outcome measure participant's status at the time of sampling were evaluable for treatment-naive and treated.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Epidermal Growth Factor Receptor (EGFR) Status [3 years]
In this outcome measure EGFR status of participants were evaluable for not tested, wild type and mutant.
- Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Knowledge Representation for Autonomous Systems (KRAS) Status [3 years]
In this outcome measure KRAS status of participants were evaluable for not tested, wild type, and mutant.
- Percentage Agreement Between Vysis Fluorescent In Situ Hybridization (FISH) and Ventana Immunohistochemistry (IHC) Methods for ALK Rearrangement Detection [3 years]
Percent overall agreement between Vysis ALK-FISH and Ventana ALK IHC tests and its 95% CI is reported in this outcome measure.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
- Histological confirmation of nonsquamous NSCLC, with any TNM stage. 2. Available and sufficient tissue sample for ALK testing 3.Tissue samples are less than 5 years old 4.Routinely processed formalin-fixed, paraffin-embedded tissue samples only (see exclusion criteria pertaining to tissue samples).
5.Histological sections mounted on glass slides must not be older than 3 months 6.Age > 18 years 7.Any ECOG Performance status 8.Still alive, or death confirmed before inclusion, or is unknown 9.Disease diagnosis and/or treatment in one of the centers, in the last 5 years, assigned to participate in the study; 10.Written informed consent for general investigational testing was previously obtained, or specifically obtained for this retrospective epidemiology study, or having a documented waiver for the Informed consent document use, as required by local regulatory authorities, &/or Research Ethics committee/Institutional Review Board.
Exclusion Criteria:
- 1- Tumor tissue samples older than 5 year period or samples not properly stored.
2-Tumor tissue samples fixed by using AFA, B5, Bouin's, 95% ETOH, & alcohol fixatives.
3-Under-fixed tissue samples (i.e. < 6 hrs) 4-Tumor tissue samples that have been subject to any decalcification processes. 5-Recycled paraffin-embedded tissue samples. 6-Cut slides stored longer than 3 months. 7-Insufficient tissue samples with less tumor cells & high amount of necrosis.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Cancer Institute | Cairo / Misr Al Qadimah | Egypt | ||
| 2 | National Cancer Institute | Cairo | Egypt | ||
| 3 | American University in Beirut | Beirut | Lebanon | ||
| 4 | American University of Beirut | Beirut | Lebanon | ||
| 5 | Institut National d'Oncologie | Rabat | Morocco | ||
| 6 | King Faisal Specialty Hospital, Riyadh/Oncology Department | Riyadh 12713 | Saudi Arabia | ||
| 7 | King Abdulaziz Medical City - National Guard Hospital | Riyadh | Saudi Arabia | ||
| 8 | King Faisal Specialty Hospital | Riyadh | Saudi Arabia | ||
| 9 | National Guard Hospital | Riyadh | Saudi Arabia | ||
| 10 | Tawam Hospital | Al Ain/Al Maqam | United Arab Emirates | ||
| 11 | Tawam Hospital | Al Ain | United Arab Emirates |
Sponsors and Collaborators
- Pfizer
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
More Information
Additional Information:
Publications
None provided.- A8081046
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of Middle East North Africa (MENA) previously diagnosed with non-small cell lung cancer (NSCLC) were tested retrospectively for the prevalence of anaplastic lymphoma kinase (ALK) rearrangement. |
| Period Title: Overall Study | |
| STARTED | 449 |
| COMPLETED | 449 |
| NOT COMPLETED | 0 |
Baseline Characteristics
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Overall Participants | 449 |
| Age, Customized (Number) [Number] | |
| 18 to 65 years |
272
60.6%
|
| Greater than equal to 65 years |
157
35%
|
| Missing |
20
4.5%
|
| Sex: Female, Male (Count of Participants) | |
| Female |
141
31.4%
|
| Male |
308
68.6%
|
| Race/Ethnicity, Customized (Number) [Number] | |
| Arabic |
389
86.6%
|
| White / Caucasian |
54
12%
|
| Other |
5
1.1%
|
| Missing |
1
0.2%
|
Outcome Measures
| Title | Percentage of Participants With Prevalence of Anaplastic Lymphoma Kinase (ALK) Rearrangement |
|---|---|
| Description | Participants with prevalence of ALK rearrangement were positive for ALK: defined as presence of strong granular cytoplasmic staining in tumor cells (any percentage of positive tumor cells). |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| Full analysis set (FAS). |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 449 |
| Number (95% Confidence Interval) [percentage of participants] |
8.69
1.9%
|
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Gender |
|---|---|
| Description | In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the gender of study participants. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| Male |
10.1
2.2%
|
| Female |
5.7
1.3%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.1304 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Method of Estimation | Estimation Parameter | Odds Ratio (OR) |
| Estimated Value | 1.85 | |
| Confidence Interval |
(2-Sided) 95% 0.80 to 4.77 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Race |
|---|---|
| Description | In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the race of study participants. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| White /Caucasian |
11.1
2.5%
|
| Arabic |
8.5
1.9%
|
| Others |
0
0%
|
| Missing |
0
0%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.6422 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Smoking History |
|---|---|
| Description | In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the smoking history of study participants as participants who never smoked, current smoker and ex-smoker. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| Never |
9.0
2%
|
| Current |
7.5
1.7%
|
| Ex-smoker |
5.8
1.3%
|
| Unknown |
11.9
2.7%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.4524 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Tumor Histologic Diagnosis |
|---|---|
| Description | In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the diagnosis of tumor histology of study participants. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| Adenocarcinoma: Positive |
8.6
1.9%
|
| Large cell carcinoma: Positive |
16.7
3.7%
|
| Not specified |
0
0%
|
| Others |
9.1
2%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.9010 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Tumor Stage |
|---|---|
| Description | In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the tumor stage of study participants. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| Stage 1 |
6.3
1.4%
|
| Stage 2 |
7.8
1.7%
|
| Stage 3 |
6.3
1.4%
|
| Stage 3 A |
0
0%
|
| Stage 3 B |
10.0
2.2%
|
| Stage 4 |
10.0
2.2%
|
| Missing |
7.0
1.6%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.9067 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Treatment Type |
|---|---|
| Description | In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the treatment type of study participants. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| Surgery with chemotherapy |
7.5
1.7%
|
| Surgery without chemotherapy |
5.2
1.2%
|
| Targeted therapy |
10.0
2.2%
|
| Chemotherapy only |
10.4
2.3%
|
| Other |
7.8
1.7%
|
| Unknown |
9.9
2.2%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.8785 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Progression Free Survival (PFS) |
|---|---|
| Description | In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the PFS of study participants. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 150 |
| Number [percentage of participants] |
8.0
1.8%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.9231 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Line of Therapy |
|---|---|
| Description | In this outcome measure, percentage of participants with association of ALK rearrangement were evaluated and categorized in terms of the line of therapy of study participants. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| First-line |
9.1
2%
|
| Second-line |
8.5
1.9%
|
| Unknown |
9.4
2.1%
|
| Missing |
3.1
0.7%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.9780 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Overall Response (OR) |
|---|---|
| Description | Percentage of participants with best overall response. Complete response (CR) is equal to (=) disappearance of all target lesions. Partial Response (PR) = greater than equal to (>=) 30% decrease in sum of longest dimensions of lesions taking as reference baseline sum longest dimensions. Progressive disease (PD) >= 20% increase in sum of longest dimensions of lesions taking as a reference smallest sum of the longest dimensions since treatment start, or the appearance of >= 1 new lesion. Stable disease (SD) =neither shrinkage for PR or increase for PD taking as reference smallest sum of longest dimensions since treatment start. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| CR |
14.3
3.2%
|
| PR |
20.0
4.5%
|
| PD |
7.6
1.7%
|
| SD |
1.8
0.4%
|
| Unknown |
9.9
2.2%
|
| Missing |
0
0%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.1144 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Participant's Status |
|---|---|
| Description | In this outcome measure participant's status at the time of sampling were evaluable for treatment-naive and treated. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| Treatment-naive |
8.2
1.8%
|
| Treated |
11.1
2.5%
|
| Unknown |
33.3
7.4%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.0862 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Epidermal Growth Factor Receptor (EGFR) Status |
|---|---|
| Description | In this outcome measure EGFR status of participants were evaluable for not tested, wild type and mutant. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| Not tested |
12.0
2.7%
|
| Wild type |
6.8
1.5%
|
| Mutant |
0
0%
|
| Unknown |
0
0%
|
| Other |
14.3
3.2%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.0294 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage of Participants With Association of Anaplastic Lymphoma Kinase (ALK) Rearrangement by Knowledge Representation for Autonomous Systems (KRAS) Status |
|---|---|
| Description | In this outcome measure KRAS status of participants were evaluable for not tested, wild type, and mutant. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure and "number analyzed" signifies the participants evaluable at specific categories. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 448 |
| Not tested |
9.0
2%
|
| Wild type |
0
0%
|
| Mutant |
0
0%
|
| Unknown |
0
0%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Non-Small Cell Lung Cancer |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.6877 |
| Comments | ||
| Method | Cochran-Mantel-Haenszel | |
| Comments | ||
| Title | Percentage Agreement Between Vysis Fluorescent In Situ Hybridization (FISH) and Ventana Immunohistochemistry (IHC) Methods for ALK Rearrangement Detection |
|---|---|
| Description | Percent overall agreement between Vysis ALK-FISH and Ventana ALK IHC tests and its 95% CI is reported in this outcome measure. |
| Time Frame | 3 years |
Outcome Measure Data
| Analysis Population Description |
|---|
| FAS. Here, "Overall Number of Participants Analyzed" signifies participants who were evaluable for this outcome measure. |
| Arm/Group Title | Non-Small Cell Lung Cancer |
|---|---|
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. |
| Measure Participants | 129 |
| Number (95% Confidence Interval) [percentage agreement] |
98.45
|
Adverse Events
| Time Frame | Not applicable as adverse events was not planned to be collected during the study | |
|---|---|---|
| Adverse Event Reporting Description | Due to the non-interventional nature of the study, adverse events were not collected during the study. | |
| Arm/Group Title | Non-Small Cell Lung Cancer | |
| Arm/Group Description | Tissue samples of participants of MENA previously diagnosed with NSCLC were tested retrospectively for the prevalence of ALK rearrangement. | |
All Cause Mortality |
||
| Non-Small Cell Lung Cancer | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/0 (NaN) | |
Serious Adverse Events |
||
| Non-Small Cell Lung Cancer | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/0 (NaN) | |
Other (Not Including Serious) Adverse Events |
||
| Non-Small Cell Lung Cancer | ||
| Affected / at Risk (%) | # Events | |
| Total | 0/0 (NaN) | |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.
Results Point of Contact
| Name/Title | Pfizer ClinicalTrials.gov Call Center |
|---|---|
| Organization | Pfizer Inc. |
| Phone | 1-800-718-1021 |
| ClinicalTrials.gov_Inquiries@pfizer.com |
- A8081046